Aquavit Pharmaceuticals

Aquavit Pharmaceuticals is a clinical-stage biotech company pioneering personalized healthcare via advanced delivery platforms. Its core assets include DTX-021, a botulinum toxin in development for aesthetic and therapeutic indications, and the commercial AQUAGOLD® microchannel delivery device. The company leverages a network of high-profile clinical investigators and is progressing DTX-021 through the FDA regulatory pathway, with recent IND clearances marking a key transition into clinical trials. Its strategy targets the large and growing neuromodulator and precision dermatology markets.

Proprietary drug delivery systems including the Aquavit Skin Application Platform (A.S.A.P.) featuring microchannel technology for intradermal delivery of therapeutics, commercialized as the AQUAGOLD® device.

In neuromodulators, Aquavit faces dominant competitors like AbbVie (BOTOX®), Galderma (Dysport®), and Merz (Xeomin®). In the drug delivery device space for aesthetics, it competes with companies like InMode, Candela, and other microneedling/ delivery system providers. Its strategy combines a therapeutic candidate with a proprietary delivery device to differentiate itself.